Brk/PTK6 Antibody (YA4758)

Cat. No.: HY-P85066: Data Sheet User Guide for Antibodies
FAQs
Technical Support

Brk/PTK6 Antibody (YA4758) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Brk/PTK6.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

Brk/PTK6 Antibody (YA4758) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Brk/PTK6.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 52 kDa;

Species Reactivity

Human

SwissProt ID

Q13882

Gene ID

5753 [NCBI]

Immunogen

Purified recombinant fragment of human Brk expressed in E. Coli.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-1:2000
ELISA ELISA: Enzyme Linked Immunosorbent Assay	1:10000

Purity	affinity purified.	Conjugation	Non-conjugated
Modification	Unmodified

Appearance

Liquid

Formulation

Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth. Function seems to be context dependent and differ depending on cell type, as well as its intracellular localization. A number of potential nuclear and cytoplasmic substrates have been identified. These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B and a variety of signaling molecules: ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Phosphorylates the GTPase-activating protein ARAP1 following EGF stimulation which enhances EGFR signaling by delaying EGFR down-regulation (PubMed:20554524). Also associates with a variety of proteins that are likely upstream of PTK6 in various signaling pathways, or for which PTK6 may play an adapter-like role. These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6 promotes cellular differentiation and apoptosis. In tumors PTK6 contributes to cancer progression by sensitizing cells to mitogenic signals and enhancing proliferation, anchorage-independent survival and migration/invasion. Association with EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 kinase. Contributes to migration and proliferation by contributing to EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes association with RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. Nuclear PTK6 may be important for regulating growth in normal epithelia, while cytoplasmic PTK6 might activate oncogenic signaling pathways; Inhibits PTK6 phosphorylation and PTK6 association with other tyrosine-phosphorylated proteins

Subcellular Localization：Cytoplasm; Nucleus; Cell projection, ruffle; Membrane

Expression：
Tissue_specificity:Epithelial-specific expression. Extremely high expression levels in the colon, high levels in the small intestine and prostate, and low levels in some fetal tissues. Not expressed in breast or ovarian tissues, but expressed in a high proportion of breast and ovarian cancers. Overexpressed in some metastatic melanomas, lymphomas, colon cancers, squamous cell carcinomas, and prostate cancers. Also found in melanocytes. Not expressed in the heart, brain, placenta, lungs, liver, skeletal muscle, kidneys, and pancreas. Isomer 2 is present in prostatic epithelial cell lines derived from normal prostate and prostate adenocarcinoma, as well as in various other cell lines.

Isoforms & Post-Translational Modification：Q13882 has 2 isomers: Q13882-1: 51834 Da (predicted); Q13882-2: 14465 Da (predicted).
Autophosphorylated. Autophosphorylation of Tyr-342 leads to an increase of kinase activity. Tyr-447 binds to the SH2 domain when phosphorylated and negatively regulates kinase activity

Subunit：Interacts (via SH3 and SH2 domains) with KHDRBS1. Interacts (via SH3 and SH2 domains) with phosphorylated IRS4. Interacts with ADAM15. Interacts (via SH3 domain) with SFPQ. Interacts with EGFR and ERBB2.

Synonyms

PTK6; BRK; Protein-tyrosine kinase 6; Breast tumor kinase; Tyrosine-protein kinase BRK

Documentation

User Guide for Antibodies (1077 KB)